IP Library › Granted Patent US 10,421,787
Granted Patent B2
US 10,421,787 · App. 15/405,787 · Granted Sep 24, 2019

Process of preparing guanylate cyclase C agonisys

Inventors: Juncai Bai (North Augusta, SC); Ruoping Zhang (North Augusta, SC); Jun Jian (Shanghai, CN); Junfeng Zhou (Shanghai, CN); Qiao Zhao (Shanghai, CN); Guoquing Zhang (Shanghai, CN); Kunwar Shailubhai (Audubon, PA); Stephen Comiskey (Doylestown, PA); Rong Feng (Langhorne, PA)
Assignee: Bausch Health Ireland Limited
C07K7/64C07K7/08C07K14/195
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,421,787
App. No.
15/405,787
Granted
Sep 24, 2019
Kind
B2
Abstract

The invention provides processes of preparing a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-249 described herein.

Claims (8)

1. A purified peptide comprising the GCC agonist sequence of SEQ ID NO: 1, wherein the peptide has a bulk density of no less than 0.4 g/mL and wherein the peptide has a tap density of no less than 0.6 g/mL.

2. The purified peptide of claim 1 , wherein the peptide has a chromatographic purity of no less than 97%.

3. The purified peptide of claim 2 , wherein the average total impurities is less than 3%.

4. The purified peptide of claim 3 , wherein peptide is substantially free of impurities selected from acetonitrile, acetamide, alcohols, ammonium, and TFA.

5. The purified peptide of claim 1 , wherein peptide is substantially free of water.

6. The purified peptide of claim 5 , wherein the average water content of the peptide is less than 10% (w/w).

7. The purified peptide of claim 1 , wherein the peptide is substantially free of topoisomers.

8. The purified peptide of claim 1 , wherein the approximate yield of the peptide is greater than 15% (w/w).

Assignments (10)
U.S. PATENT SECURITY AGREEMENT Recorded Nov 25, 2025
From: BAUSCH HEALTH IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 073715/0375 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061882/0708 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 062078/0276 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
RELEASE OF SECURITY INTEREST Recorded Mar 6, 2019
From: CRG SERVICING LLC
To: SYNERGY PHARMACEUTICALS INC.
Reel/Frame 048521/0005 →
SECURITY INTEREST Recorded Sep 5, 2017
From: SYNERGY PHARMACEUTICALS INC.
To: CRG SERVICING LLC, AS AGENT
Reel/Frame 043488/0741 →
Continuity (3)
Continuation 14001638
Provisional Application 61447891 · Mar 1, 2011
Related Publication 20170129925A1 · May 11, 2017